Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the adverse events (AEs) that are associated with enzalutamide (Xtandi) and apalutamide (Erleada) in prostate cancer.
Deborah A. Bradley, MD
Advertisement
Articles by Deborah A. Bradley, MD
Deborah A. Bradley, MD, oncologist, Levine Cancer Institute, discusses next steps for research in nonmetastatic prostate cancer.
Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the importance of exercise in the management of prostate cancer treatment-related adverse events.
Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, discusses the impact of the recently published SPARTAN and PROSPER trials in nonmetastatic castration-resistant prostate cancer.
Advertisement
Latest Updated Articles
Dr. Bradley on Impact of SPARTAN and PROSPER in Nonmetastatic CRPCPublished: October 19th 2018 | Updated:
Dr. Bradley on Exercise in Treatment-Related AE ManagementPublished: November 16th 2018 | Updated:
Dr. Bradley on Next Steps for Research in Nonmetastatic Prostate CancerPublished: November 29th 2018 | Updated:
Dr. Bradley on Adverse Events Associated With Enzalutamide and Apalutamide in Prostate CancerPublished: July 26th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5